# Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)

> **NCT02403674** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 734 (actual)

## Conditions studied

- Human Immunodeficiency Virus (HIV)

## Interventions

- **DRUG:** Doravirine, Tenofovir, Lamivudine
- **DRUG:** ATRIPLA™
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02403674
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-05
- **Primary completion:** 2017-03-20
- **Final completion:** 2023-09-07
- **Target enrollment:** 734 (ACTUAL)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02403674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02403674, "Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02403674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*